Total Payments
$639,121
2024 Payments
$26,737
Companies
42
Transactions
1,945
Medicare Patients
21,686
Medicare Billing
$4.6M
Payment Breakdown by Category
Other$338,060 (52.9%)
Consulting$127,464 (19.9%)
Travel$100,736 (15.8%)
Research$38,629 (6.0%)
Food & Beverage$33,484 (5.2%)
Education$749.55 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $335,735 | 150 | 52.5% |
| Consulting Fee | $127,464 | 37 | 19.9% |
| Travel and Lodging | $100,736 | 260 | 15.8% |
| Unspecified | $38,629 | 20 | 6.0% |
| Food and Beverage | $33,484 | 1,453 | 5.2% |
| Honoraria | $2,325 | 2 | 0.4% |
| Education | $749.55 | 23 | 0.1% |
Payments by Type
General
$600,493
1,925 transactions
Research
$38,629
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $207,285 | 309 | $0 (2024) |
| ABBVIE INC. | $139,492 | 522 | $0 (2024) |
| Amgen Inc. | $68,034 | 220 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $61,507 | 91 | $0 (2019) |
| Celgene Corporation | $54,670 | 89 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $32,533 | 120 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $21,442 | 2 | $0 (2019) |
| PFIZER INC. | $10,963 | 125 | $0 (2024) |
| Janssen Biotech, Inc. | $8,828 | 68 | $0 (2023) |
| Eli Lilly and Company | $7,212 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $26,737 | 158 | ABBVIE INC. ($12,817) |
| 2023 | $52,691 | 201 | Amgen Inc. ($31,051) |
| 2022 | $60,776 | 225 | ABBVIE INC. ($37,288) |
| 2021 | $34,476 | 203 | AbbVie Inc. ($15,923) |
| 2020 | $60,087 | 250 | Lilly USA, LLC ($28,307) |
| 2019 | $205,982 | 390 | Lilly USA, LLC ($72,341) |
| 2018 | $125,968 | 268 | Lilly USA, LLC ($67,472) |
| 2017 | $72,404 | 250 | Lilly USA, LLC ($29,345) |
All Payment Transactions
1,945 individual payment records from CMS Open Payments — Page 1 of 78
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | Cash or cash equivalent | $147.92 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/17/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: Immunology | ||||||
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $5.04 | General |
| Category: IMMUNOLOGY | ||||||
| 12/15/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $12.08 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $11.91 | General |
| Category: Bone Health | ||||||
| 12/11/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $3.71 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $712.16 | General |
| 12/06/2024 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $265.55 | General |
| 12/06/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $149.99 | General |
| 12/06/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $141.70 | General |
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.72 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $29.76 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/02/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/27/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $23.47 | General |
| Category: Inflammation | ||||||
| 11/26/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: Inflammation | ||||||
| 11/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $4.57 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Safety, Toelrability and PK Study of Multiple Rising Doses of of MLN9708 for the Treatment of Subjects ith ISN-RPS Class III or IV Lupus Nephritis | Takeda Pharmaceuticals U.S.A., Inc. | $21,424 | 1 |
| A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LY3361237 IN HEALTHY SUBJECTS | Eli Lilly and Company | $5,389 | 2 |
| CC-10004-PSA-006 | Celgene Corporation | $2,950 | 1 |
| A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Na?ve Subjects with Moderately to Severely Active Rheumatoid Arthritis | ABBVIE INC. | $2,000 | 1 |
| M13-545 | AbbVie, Inc. | $2,000 | 1 |
| CC-10004-PSA-005 | Celgene Corporation | $1,488 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $1,218 | 2 |
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, | GlaxoSmithKline, LLC. | $984.57 | 5 |
| A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Eli Lilly and Company | $490.07 | 3 |
| CC-10004-PSA-004 - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis and a | Celgene Corporation | $442.00 | 1 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | CSL Behring | $128.76 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | Eli Lilly and Company | $114.46 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 51 | 5,002 | 193,921 | $4.9M | $1.0M |
| 2022 | 35 | 4,669 | 189,521 | $4.5M | $1.1M |
| 2021 | 36 | 5,896 | 171,969 | $4.2M | $1.2M |
| 2020 | 41 | 6,119 | 166,061 | $4.4M | $1.3M |
Total Patients
21,686
Total Services
721,472
Medicare Billing
$4.6M
Procedure Codes
163
All Medicare Procedures & Services
163 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 68 | 163,200 | $3.3M | $634,544 | 19.4% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 23 | 15,540 | $419,580 | $123,859 | 29.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 425 | 761 | $223,734 | $66,744 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 488 | 1,048 | $207,504 | $60,291 | 29.1% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 11 | 3,700 | $266,400 | $28,145 | 10.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 489 | 1,420 | $51,120 | $14,209 | 27.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 569 | 1,578 | $23,670 | $12,971 | 54.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 80 | 80 | $45,280 | $12,111 | 26.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 480 | 1,406 | $46,398 | $10,393 | 22.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 114 | 951 | $62,766 | $10,038 | 16.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 34 | 90 | $41,400 | $7,510 | 18.1% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 495 | 1,391 | $30,602 | $6,855 | 22.4% |
| 73120 | X-ray of hand, 2 views | Office | 2023 | 121 | 242 | $19,118 | $5,019 | 26.3% |
| 73100 | X-ray of wrist, 2 views | Office | 2023 | 117 | 234 | $20,592 | $4,861 | 23.6% |
| 73620 | X-ray of foot, 2 views | Office | 2023 | 120 | 238 | $18,564 | $4,487 | 24.2% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 224 | 229 | $20,381 | $4,441 | 21.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 34 | 34 | $15,436 | $3,799 | 24.6% |
| 73600 | X-ray of ankle, 2 views | Office | 2023 | 81 | 162 | $13,122 | $3,302 | 25.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 16 | 129 | $13,545 | $2,620 | 19.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 23 | 50 | $12,050 | $2,611 | 21.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 18 | 54 | $11,610 | $2,471 | 21.3% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 55 | 55 | $14,960 | $1,931 | 12.9% |
| 80074 | Acute hepatitis panel | Office | 2023 | 37 | 38 | $6,118 | $1,774 | 29.0% |
| 73610 | X-ray of ankle, minimum of 3 views | Office | 2023 | 35 | 70 | $6,440 | $1,730 | 26.9% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 83 | 131 | $7,860 | $1,539 | 19.6% |
About Dr. Jacob Aelion, M.D
Dr. Jacob Aelion, M.D is a Specialist healthcare provider based in Jackson, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1679551501.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jacob Aelion, M.D has received a total of $639,121 in payments from pharmaceutical and medical device companies, with $26,737 received in 2024. These payments were reported across 1,945 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($335,735).
As a Medicare-enrolled provider, Aelion has provided services to 21,686 Medicare beneficiaries, totaling 721,472 services with total Medicare billing of $4.6M. Data is available for 4 years (2020–2023), covering 163 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Jackson, TN
- Active Since 12/30/2005
- Last Updated 04/23/2025
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1679551501
Products in Payments
- TALTZ (Drug) $90,432
- RINVOQ (Biological) $73,870
- Otezla (Drug) $71,629
- OLUMIANT (Drug) $42,415
- KEVZARA SARILUMAB INJECTION (Biological) $37,392
- TAVNEOS (Drug) $32,024
- KEVZARA (Biological) $25,855
- Rinvoq (Biological) $21,858
- COSENTYX (Biological) $20,464
- XELJANZ (Drug) $10,718
- TREMFYA (Drug) $10,425
- Tavneos (Drug) $10,422
- RINVOQ (Drug) $10,014
- SKYRIZI (Biological) $8,273
- KRYSTEXXA (Biological) $5,964
- DUZALLO (Drug) $5,893
- ILARIS (Biological) $4,132
- COSENTYX (Drug) $3,978
- Cimzia (Drug) $1,912
- KRYSTEXXA (Drug) $1,713
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Jackson
Dr. Ruth Fredericks, M.d, M.D
Specialist — Payments: $985,371
Specialist $985,371
Dr. Satish Odhav, M.d, M.D
Specialist — Payments: $707,119
Specialist $707,119
Dr. Richard Yelverton, M.d, M.D
Specialist — Payments: $90,656
Specialist $90,656
Lori Reed, Md, MD
Specialist — Payments: $44,584
Specialist $44,584
Maria Rappai, M.d, M.D
Specialist — Payments: $16,058
Specialist $16,058
Dr. Steven Patterson, M.d, M.D
Specialist — Payments: $15,849
Specialist $15,849